Overview
- 13 inspections across 12 sites are on record.
- 1 Form 483 observation is attributed to this investigator.
- Most recent recorded activity is 2026-02-03.
At a glance
Inspections
13
Sites
12
Observations
1
Career since
Jul 2018
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Chinese Peptide Company | 3 Feb 2026 | Human Drugs | On file |
| Chugai Pharma Manufacturing Co., Ltd | 29 Mar 2024 | Human Drugs | On file |
| AbbVie Bioresearch Center | 30 Jan 2024 | Human Drugs | On file |
| Samsung Biologics Co., Ltd. | 1 Sep 2023 | Human Drugs | On file |
| Alexion Pharma International Operations Limited | 24 Jan 2023 | Human Drugs | On file |
Sites inspected
Chinese Peptide CompanyHangzhou, China1 insp.
Chugai Pharma Manufacturing Co., LtdKita, Japan1 insp.
AbbVie Bioresearch CenterWorcester, United States1 insp.
Samsung Biologics Co., Ltd.Yeonsu District, Korea (the Republic of)1 insp.
Alexion Pharma International Operations LimitedDublin 15, Ireland1 insp.
Co-investigators
Investigators who share inspections with this person.
Zhong Li3 shared
Michael Shanks3 shared
Hamet M Toure2 shared
Yiwei Li1 shared
Thuy T Nguyen1 shared
Hyung-Yul Lee1 shared
Dogbeda F Mackenzie1 shared
Wayne E Seifert1 shared
Jeffrey P Raimondi1 shared
Wendy G Tan1 shared
Full investigator report
Get the verbatim findings behind Jacek Cieslak's 1 observation
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site